has been reported by other groups, 5, 6 sometimes under the rubric of ''late-onset myoclonic epilepsy in Down syndrome'' (LOMEDS).
As part of ongoing studies of DS patients seen in the Cognitive Function Clinic (CFC) at the regional neuroscience centre in Liverpool, and in general neurological clinics undertaken by one consultant neurologist, 7 records of all DS patients seen over a 9-year-period (January 2002-December 2010 inclusive) were reviewed. Following De Simone et al., 1 diagnosis of senile myoclonic epilepsy was based on the observation of both progressive cognitive decline or frank dementia and myoclonic jerks, particularly on awakening. There were 24 referrals involving a total of 19 DS patients (one patient referred twice, two patients referred 3 times) identified from clinic records (M:F = 9:10; age range at first referral 21-64 years, median = 47 years) from a total of 9468 new patient consultations (=0.20%). Although the number of DS cases is small, nonetheless this may represent over 10% of the estimated total number of DS patients aged 18-64 in Liverpool. 8 Of these 19 DS patients, 13 had attended general neurology clinics (13/ 8168 = 0.16%) and 6 had attended the CFC (6/1300 = 0.46%). Of those 13 patients attending the general neurology clinic, all but one was referred for episodes of loss of consciousness, the exception being a patient with limb tremor who was being treated with valproate for mood stabilization. Ten patients were diagnosed with epilepsy, the other two with syncopal events. Seven of the patients, all with epilepsy, also had a history of cognitive decline sufficient to amount to dementia. Of these, 3 had myoclonus and tonic-clonic seizures.
Those patients attending CFC were all referred for perceived cognitive decline; all 6 were diagnosed with dementia. Two of these patients also had epileptic seizures but without a history of myoclonic jerks, another had myoclonic jerks but not seizures.
Hence, both cognitive decline and myoclonus, sufficient for a diagnosis of senile myoclonic epilepsy, 1 were observed in four patients (=21%). A further six patients had cognitive decline and epileptic seizures but with no report or observation of myoclonus. As De Simone et al. note, 1 the latter may be overlooked, in which case these six patients may also have had senile myoclonic epilepsy. If so, the frequency of this condition rises to 53% (=10/19).
The shortcomings of the current data notwithstanding, it is evident that senile myoclonic epilepsy in DS is not a rarity.
Epileptogenesis in senile myoclonic epilepsy in DS is presumably similar to that in AD patients. 9 Overexpression of amyloid bpeptide (Ab) species derived from the amyloid precursor protein (APP) gene on chromosome 21, present in three copies in DS, is thought to be central to the development of AD brain pathology which invariably develops after the age of 50 years. 10 Myoclonus and seizures are common in AD patients with presenilin 1 gene mutations which increase Ab expression 11 and there is a high seizure frequency (>50%) in AD patients with APP duplications. 12 
